Approach to Management of Premature Ventricular Contractions

[41] Crow RS(2019)Premature ventricular contraction diurnal profiles predict distinct clinical characteristics and beta‐blocker responses Journal of Cardiovascular Electrophysiology 30 836-2651

[42] Rautaharju PM(2017)2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America J Am Coll Cardiol 70 776-100

[43] Heiss G(2012)Benign symptomatic premature ventricular complexes: short- and long-term efficacy of antiarrhythmic drugs and radiofrequency ablation Kardiol Pol 70 351-788

[44] Ofoma U(2015)Advances in the pharmacologic treatment of ventricular arrhythmias Expert Opin Pharmacother 16 2637-233

[45] He F(1983)Idiopathic paroxysmal ventricular tachycardia with a QRS pattern of right bundle branch block and left axis deviation: a unique clinical entity with specific properties Am J Cardiol 52 95-42

[46] Shaffer ML(1991)Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial N Engl J Med 324 781-682

[47] Naccarelli GV(1992)Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction N Engl J Med 327 227-372

[48] Liao D(1989)Electropharmacology of amiodarone therapy initiation. Time courses of onset of electrophysiologic and antiarrhythmic effects Circulation. 80 34-516

[49] Duffee DF(1997)Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian amiodarone myocardial infarction arrhythmia trial investigators Lancet. 349 675-197

[50] Shen WK(1976)Observations on the efficacy and pharmacokinetics of sotalol after oral administration Eur J Clin Pharmacol 09 367-42

[41] Crow RS(2019)Premature ventricular contraction diurnal profiles predict distinct clinical characteristics and beta‐blocker responses Journal of Cardiovascular Electrophysiology 30 836-2651

[42] Rautaharju PM(2017)2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America J Am Coll Cardiol 70 776-100

[43] Heiss G(2012)Benign symptomatic premature ventricular complexes: short- and long-term efficacy of antiarrhythmic drugs and radiofrequency ablation Kardiol Pol 70 351-788

[44] Ofoma U(2015)Advances in the pharmacologic treatment of ventricular arrhythmias Expert Opin Pharmacother 16 2637-233

[45] He F(1983)Idiopathic paroxysmal ventricular tachycardia with a QRS pattern of right bundle branch block and left axis deviation: a unique clinical entity with specific properties Am J Cardiol 52 95-42

[46] Shaffer ML(1991)Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial N Engl J Med 324 781-682

[47] Naccarelli GV(1992)Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction N Engl J Med 327 227-372

[48] Liao D(1989)Electropharmacology of amiodarone therapy initiation. Time courses of onset of electrophysiologic and antiarrhythmic effects Circulation. 80 34-516

[49] Duffee DF(1997)Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian amiodarone myocardial infarction arrhythmia trial investigators Lancet. 349 675-197

[50] Shen WK(1976)Observations on the efficacy and pharmacokinetics of sotalol after oral administration Eur J Clin Pharmacol 09 367-42